Osteoarthritis Trial Standards Get Forum As FDA Works To Finalize Guidance
Executive Summary
FDA is calling for a public meeting to develop a critical appraisal of aspects of osteoarthritis assessment and trial design as the agency finally revisits guidance on clinical development programs
You may also be interested in...
US FDA’s Non-Guidance On Osteoarthritis Drugs: Starting Over On Structural Claims
Agency essentially ruling out use of structural endpoints to support disease progression claims for osteoarthritis drugs in new draft guidance.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.